<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128322</url>
  </required_header>
  <id_info>
    <org_study_id>128HT09K</org_study_id>
    <nct_id>NCT01128322</nct_id>
  </id_info>
  <brief_title>CKD-828 Primary Hypertension Trial(Dose-selection)</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to determine the best dose combination of S-Amlodipine and
      Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a
      once daily regimen of various combinations of S-Amlodipine and Telmisartan, compared to their
      monotherapy components and placebo, in patients with stage I or II essential hypertension(a
      mean seated cuff diastolic blood pressure &gt;=95 and &lt;=115 mmHg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure(MSDBP)</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure(MSDBP)</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Systolic Blood Pressure(MSSBP)</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
    <description>Reduction of SBP ≥ 20mmHg, DBP ≥ 10mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control rate</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
    <description>Reduction SBP &lt; 140mmHg, DBP &lt; 90mmHg</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Amlodipine, Telmisartan</intervention_name>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 80mg</arm_group_label>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Amlodipine</intervention_name>
    <arm_group_label>S-Amlodipine 2.5mg</arm_group_label>
    <arm_group_label>S-Amlodipine 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan 40mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure
             &gt;=95 and &lt;=115 mmHg

          -  ability to provide written informed consent

        Exclusion Criteria:

          -  severe hypertension defined as: a mean seated cuff diastolic blood pressure &gt;=116mmHg
             or a mean seated cuff systolic blood pressure &gt;=200mmHg

          -  known or suspected secondary hypertension(ex. aortic coarctation, Primary
             hyperaldosteronism, renal artery stenosis, pheochromocytoma)

          -  has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or
             myocardial infarction, arrhythmia within the past three months

          -  has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6
             months

          -  Type I Diabets Mellitus, Type II Diabetes Mellitus with poor glucose control as
             defined by fasting glucosylated hemoglobin(HbA1c) &gt; 8%

          -  known severe or malignant retinopathy

          -  hepatic or renal dysfunction as defined by the following laboratory parameters:
             AST/ALT &gt; UNL X 2, serum creatinine &gt; UNL X 1.5

          -  acute or chronic inflammatory status need to treatment

          -  need to additional antihypertensive drugs during the study

          -  need to concomitant medications known to affect blood pressure during the study

          -  history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers

          -  known hypersensitivity related to either study drug

          -  history of drug or alcohol dependency

          -  any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of investigational products(ex.
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,
             active inflammatory bowel syndrome within 12 months prior to screening, currently
             active gatritis, ulcers of gastrointetinal/rectal bleeding, impaired pancreatic
             fuction such as pancreatitis,obstructions of the urinary tract or difficulty in
             voiding)

          -  cannot swallow investigational products

          -  administration of other study drugs within 4 weeks prior to randomization

          -  premenopausal women(last menstration &lt; 1year) not using adequte contraception,
             pregnant or breast-feeding

          -  history of malignancy including leukemia and lymphoma within the past 5 years

          -  in investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital in Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National Uiversity Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DonGuk University International Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kandong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, The catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uijeongbu St. Mary's Hospital, The catholic University of Korea</name>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <last_update_submitted>April 22, 2011</last_update_submitted>
  <last_update_submitted_qc>April 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jin Kim / Director</name_title>
  </responsible_party>
  <keyword>CKD-828</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Primary Hypertension</keyword>
  <keyword>S-Amlodipine</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Factorial</keyword>
  <keyword>Phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

